The prognosis for esophageal cancer, one of the malignancies that responds least to cancer therapy, has not improved despite several breakthroughs in treatment. Improving patient outcomes depends on finding biomarkers and comprehending the molecular causes of esophageal cancer.

We wanted to create a risk score based on platelet-related gene signatures for prognosis prediction since the expression of platelet-related genes is strongly linked to patient prognosis.

To predict esophageal cancer prognosis, a risk model and nomogram constructed based on platelet-related gene signatures and clinical factors associated with prognosis could be utilized.

We constructed a trustworthy platelet-related gene signature to predict the prognosis of esophageal cancer using 151 samples of the disease. Then, an integrated nomogram for clinical practice was created utilizing a combined risk score, risk score, and TNM stage. The prognostic accuracy of the model was also supported by the receiver operating characteristic curve, concordance index, and related calibration curve.

The survival curve was created after constructing a prognostic risk model based on four platelet genes associated with prognosis. Patients in the high-risk group had a considerably lower life expectancy than those in the low-risk group, according to the Kaplan-Meier survival analysis. The risk score was an independent factor in predicting survival, according to results from both univariate and multivariate Cox regression analyses.

We identified a four-gene signature, constructed a risk score, and developed a prediction nomogram for patients with esophageal cancer based on the risk score, TNM staging, and histopathological type.

Identification and prediction of prognostic indicators are essential for esophageal cancer patients.